Comparative Pharmacology
Head-to-head clinical analysis: TEMAZ versus TRIAZOLAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TEMAZ versus TRIAZOLAM.
TEMAZ vs TRIAZOLAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Temazepam, a benzodiazepine, enhances the effect of gamma-aminobutyric acid (GABA) at the GABA-A receptor, increasing chloride ion conductance and causing neuronal hyperpolarization, leading to anxiolytic, sedative, and hypnotic effects.
Triazolam is a benzodiazepine that binds to GABA-A receptors at the alpha-1 subunit, potentiating the inhibitory effects of GABA and increasing chloride ion influx, leading to neuronal hyperpolarization and sedation.
Temazepam 15-30 mg orally at bedtime, up to 60 mg if needed.
0.125-0.25 mg orally once daily at bedtime; maximum 0.5 mg/day.
MODERATE Risk
MODERATE Risk
Terminal elimination half-life: 1.5–2 hours; in severe renal impairment (CrCl <30 mL/min), half-life may extend to 4–6 hours, requiring dose adjustment.
Clinical Note
moderateTriazolam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Triazolam is combined with Fluticasone propionate."
Clinical Note
moderateTemazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Temazepam is combined with Fluticasone propionate."
Clinical Note
moderateTemazepam + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Temazepam."
Clinical Note
moderate1.5-5.5 hours (mean 2-4 hours) in healthy adults; prolonged in hepatic cirrhosis and elderly.
Renal: ~80% as unchanged drug and metabolites; biliary/fecal: ~20%.
Primarily renal: approximately 80% as metabolites, less than 2% unchanged; biliary/fecal: minor (about 8-10%).
Category C
Category D/X
Benzodiazepine
Benzodiazepine
Temazepam + Haloperidol
"The risk or severity of adverse effects can be increased when Temazepam is combined with Haloperidol."